• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    5/1/24 12:31:13 PM ET
    $AKAN
    $CTMX
    $CVRX
    $CVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • CytomX Therapeutics (NASDAQ:CTMX) stock increased by 154.6% to $4.15 during Wednesday's regular session. The market value of their outstanding shares is at $281.0 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 36.79% to $2.9. The market value of their outstanding shares is at $3.8 million.
    • Akanda (NASDAQ:AKAN) shares increased by 33.87% to $0.12. The company's market cap stands at $1.4 million.
    • Surmodics (NASDAQ:SRDX) shares increased by 30.14% to $33.44. The market value of their outstanding shares is at $475.9 million. As per the news, the Q2 earnings report came out today.
    • Psyence Biomedical (NASDAQ:PBM) shares increased by 27.81% to $1.15. The market value of their outstanding shares is at $15.3 million.
    • TransMedics Gr (NASDAQ:TMDX) shares rose 27.75% to $120.26. The company's market cap stands at $3.9 billion. As per the press release, Q1 earnings came out yesterday.

    Losers

    • CVRx (NASDAQ:CVRX) stock declined by 36.9% to $9.79 during Wednesday's regular session. The market value of their outstanding shares is at $211.4 million. As per the press release, Q1 earnings came out yesterday.
    • Tilray Brands (NASDAQ:TLRY) shares declined by 19.65% to $1.98. The market value of their outstanding shares is at $1.5 billion.
    • cbdMD (AMEX:YCBD) stock fell 19.11% to $0.89. The company's market cap stands at $2.7 million.
    • BiomX (AMEX:PHGE) stock decreased by 18.38% to $0.39. The company's market cap stands at $21.5 million.
    • CVS Health (NYSE:CVS) stock fell 16.94% to $56.24. The market value of their outstanding shares is at $70.8 billion. The company's, Q1 earnings came out today.
    • Mobile-health Network (NASDAQ:MNDR) stock declined by 15.5% to $20.83. The company's market cap stands at $708.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $CTMX
    $CVRX
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Surmodics Inc.
    $SRDX
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    TransMedics Group Inc.
    $TMDX
    10/23/2025$148.00Hold → Buy
    Needham
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    TransMedics Group Inc.
    $TMDX
    10/13/2025$145.00Buy
    Jefferies
    More analyst ratings

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

    NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the "Company Guide"), requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity

    3/27/26 4:30:00 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

    NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance its 2026 operations with over $3 million from internal funds, including for operations and acquisitions related to security, defense and first response. For its initial transaction, BiomX has signed a non-binding LOI with an unrelated third party to secure the exclusive distribution rights in Israel for an advanced aerial firefighting system from a drone components and payload developer. The proposed license would grant X Security & Defense the rights to distribute drone-based fire suppression solutions,

    3/26/26 8:48:01 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition

    Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its wholly owned subsidiary, First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, are pleased to announce an expansion of its dark fiber network with the addition of approximately 200 kilometres, increasing total network coverage to approximately 900 kilometres across Central Mexico.This milestone is expected to materially advance FTF's strategy to build a scaled, high-margin, cash-flow-generating digital infrastructure platform in what the Company believes is one of Latin America's most attractive and undersupplied connectivity ma

    3/26/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gallina John E

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    3/20/26 5:05:17 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Chu Yu-Waye

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:41:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mccarthy Sean A.

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:35:34 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CTMX
    $CVRX
    $CVS
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    3/27/26 4:50:53 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.

    SCHEDULE 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

    3/27/26 1:34:36 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    3/26/26 5:40:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Canaccord Genuity initiated coverage on Tilray

    Canaccord Genuity initiated coverage of Tilray with a rating of Hold

    1/27/26 9:29:20 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Financials

    Live finance-specific insights

    View All

    Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026

    NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the third fiscal quarter which ended February 28, 2026, before the financial markets open on Wednesday, April 1, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Ti

    3/25/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation Invests $2.24 Million to Strengthen Community Health in Charlotte's Historic West End

    Health Zones effort aims to improve health care access, healthy food and chronic condition support in CharlotteCHARLOTTE, N.C., March 18, 2026 /PRNewswire/ -- The CVS Health Foundation today announced the launch of its Health Zone in Charlotte with a $2.24 million investment in the Westside Wellness Collab, led by Local Initiatives Support Corporation (LISC) Charlotte to expand access to health care, healthy food and chronic condition support in Charlotte's Historic West End. "Families deserve access to quality care, healthy food and the support networks that make long‑term well

    3/18/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CTMX
    $CVRX
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care